View Author
patient abciximab creatine troponin infarction death level event placebo angioplasty creatine kinase-mb angina study kinase ratio percent kinase-mb lesion troponin t levels treatment group procedure creatine kinase ratio troponin t serum month milliliter value enzyme follow-up 30 days table trial outcome creatine kinase end-point heart angiographic damage angiogram stent artery analysis 6 months ischaemia-related artery intervention serum troponin t copyright 1999 massachusetts investigator baseline revascularization randomization characteristic mortality odds ratio result benefit reduction hospital elevation placebo group eur heart j event rates periprocedural glycoprotein infarct disease angiography thrombu vessel issue ischaemia-related difference thrombus formation event rate abciximab patients placebo patients 0.12 ng lesion characteristics limit
3 Most Recent Publications
|
Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
(Article)
Brand, M.J.B.M. van den Laarman, G-J. Steg, P.G. Scheerder, I.K. de Heyndrickx, G.R. Beatt, K.J. Kootstra, J.G. Simoons, M.L. |
1999-11-19
|
|
Minimal myocardial damage during coronary intervention is associated with impaired outcome
(Article)
Simoons, M.L. Lincoff, A.M. Wieken, L.R. van der Harrington, R.A. Vahanian, A. Rutsch, W.R. Kootstra, J.G. Boersma, H. Califf, R.M. Topol, E.J. Brand, M.J.B.M. van den |
1999-08-01
|
|
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels.
(Article)
Hamm, C.W. Heeschen, C. Goldmann, B. Vahanian, A. Adgey, J. Macaya Miguel, C.M. Rutsch, W.R. Berger, J. Kootstra, J.G. Simoons, M.L. |
1999-01-01
|
